Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures.

Abstract

Lacosamide is an antiepileptic drug approved in the USA and Europe as adjunctive therapy for partial-onset seizures. Studies suggest that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels and possibly interacts with collapsin response mediator protein-2. The efficacy of lacosamide has been shown in animal models of epilepsy and Phase II/III clinical trials. Pharmacokinetic studies show that it is renally excreted, minimally bound to plasma proteins and has no known clinically relevant drug-drug interactions. Clinical trials show that lacosamide is well tolerated; the most common adverse events were dizziness, nausea and vomiting. In a Phase II/III pooled analysis, lacosamide 200 and 400 mg/day significantly reduced partial-onset seizure frequency and improved the 50% responder rate compared with placebo.

• Authors: Ahmad Beydoun, Joseph D'Souza, David Hebert, Pamela Doty
• Journal: Expert review of neurotherapeutics (Expert Rev Neurother) Vol. 9 Issue 1 Pg. 33-42 (Jan 2009) ISSN: 1744-8360 [Electronic] England
• PMID: 19102666 (Publication Type: Journal Article, Review)

Chemical References

• Acetamides
• Anticonvulsants
• Lacosamide

Topics

• Acetamides (pharmacology)
• Animals
• Anticonvulsants (pharmacology)
• Clinical Trials as Topic
• Humans
• Lacosamide
• Seizures (drug therapy)